U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1251 - 1260 of 39585 results

Status:
Investigational
Source:
NCT03801889: Phase 2 Interventional Withdrawn Iron Overload
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



SP-420 is iron chelator developed by University Of Florida Research Foundation for the treatment of iron overload disease
Status:
Investigational
Source:
NCT04467905: Phase 2 Interventional Completed Atrial Fibrillation
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.
Status:
Investigational
Source:
INN:nicametate [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Nicametate is a vasodilator, which enhances blood flow and oxygen to the brain, aids stroke recovery. It also can use for treating intermittent claudication in certain patients.
Status:
Investigational
Source:
INN:fenirofibrate
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

FENIROFIBRATE, (-)- is a metabolite of fenofibrate, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.
Status:
Investigational
Source:
NCT00063219: Phase 2 Interventional Completed Carcinoma, Non-Small-Cell Lung
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Milataxel, a taxane that binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization. Milataxel has completed phase II clinical trials for non-small cell lung cancer patients, and for colorectal cancer patients. Besides, it was studied for malignant mesothelioma. However, the drug has been discontinued due to toxicity issues at the dose level of 35 mg/m 2.
Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 125 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 131 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
NCT04052516: Phase 2 Interventional Completed Non Alcoholic Steatohepatitis (NASH)
(2019)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.
Status:
Investigational
Source:
NCT02342691: Phase 1/Phase 2 Interventional Completed Gingival Inflammation
(2015)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Benzo-lipoxin A4 as a bLXA4-ME also known as ClinRinse-1 participated in phase II clinical trials for the treatment of gingival diseases. It was shown that nano-proresolving medicines (NPRM) containing a lipoxin analog (benzo-lipoxin A4, bLXA4) was a mimetic of endogenous resolving mechanisms with potent bioactions. That offered a new therapeutic tissue-engineering approach for the treatment of chronic osteolytic inflammatory diseases.
Status:
Investigational
Source:
NCT03041116: Phase 3 Interventional Terminated Pantothenate Kinase-Associated Neurodegeneration
(2017)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Phosphopantothenic acid is an amidoalkyl phosphate that is the 4-phosphate derivative of (R)-pantothenic acid. Phosphopantothenic acid is not permeable to cell membranes due to its anionic character, consistent with the observation that systemic administration of Phosphopantothenic acid does not restore CoA levels in cellular and mouse models

Showing 1251 - 1260 of 39585 results